| AquaBounty Technologies is conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. Co. has the licensing rights for a gene construct (transgene) used to create a breed of farm-raised Atlantic salmon. Co. has obtained regulatory approval from the U.S. Food and Drug Administration for the production and sale of its genetically engineered AquAdvantage salmon product (GE Atlantic salmon) in the U.S.; from Health Canada for the production and sale of its GE Atlantic salmon product in Canada; and from National Biosafety Technical Commission for the sale of its GE Atlantic salmon product in Brazil. The AQB average annual return since 2017 is shown above.
The Average Annual Return on the AQB average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AQB average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AQB average annual return calculation with any dividends reinvested as applicable (on ex-dates).